Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 20, 2023, titled "Zydus receives USFDA approval for ZITUVIOTM to treat adult patients with type 2 diabetes mellitus".
Press Release Oct 20 2023
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The approval is based on the company's New Drug Application for Sitagliptin tablets in various strengths. This milestone reflects Zydus' commitment to providing affordable treatment options for diabetes management. The press release emphasizes the company's dedication to innovative healthcare solutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 16 2023
- Press Release Oct 06 2023
- Press Release Sep 29 2023
- Press Release Sep 20 2023
- Press Release Sep 19 2023
Later from Zydus Lifesciences
- Press Release Oct 25 2023
- Press Release Oct 30 2023
- Press Release Oct 31 2023
- Press Release Nov 02 2023
- Press Release Nov 03 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences